| COVID-19 |
1 |
0.95 |
| Biologic Therapy |
0 |
0.61 |
| COVID-19 Vaccine |
0 |
0.54 |
| Vaccines |
0 |
0.49 |
| Severe Acute Respiratory Syndrome |
0 |
0.44 |
| Immunization |
0 |
0.38 |
| Immunocompromise |
0 |
0.38 |
| Acute Respiratory Distress Syndrome |
0 |
0.35 |
| HIV Infection |
0 |
0.34 |
| Glucocorticoid |
0 |
0.25 |
| Hospital |
0 |
0.25 |
| Massachusetts |
0 |
0.25 |
| T-Lymphocyte |
0 |
0.25 |
| Transplantation |
0 |
0.25 |
| Antineoplastic Drug |
0 |
0.19 |
| Autoimmune Disease |
0 |
0.19 |
| Europe |
0 |
0.19 |
| Monoclonal Antibody |
0 |
0.19 |
| Disease-Modifying Antirheumatic Drugs |
0 |
0.13 |
| Immunoglobulin G (IgG) |
0 |
0.13 |
| Receptors |
0 |
0.13 |
| Interstitial Lung Disease |
0 |
0.09 |
| Antimetabolite |
0 |
0.06 |
| Arthritis |
0 |
0.06 |
| Clinical Guidelines |
0 |
0.06 |
| Echocardiography |
0 |
0.06 |
| Food and Drug Administration (FDA) |
0 |
0.06 |
| Grant |
0 |
0.06 |
| Lung |
0 |
0.06 |
| Lupus |
0 |
0.06 |
| Memory |
0 |
0.06 |
| Myositis |
0 |
0.06 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.06 |
| Tumor |
0 |
0.06 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.05 |
| Cardiovascular Imaging |
0 |
0.05 |